Medtronic PLC $MDT Shares Sold by American National Bank & Trust

American National Bank & Trust trimmed its position in shares of Medtronic PLC (NYSE:MDT) by 8.5% during the third quarter, HoldingsChannel reports. The institutional investor owned 82,294 shares of the medical technology company’s stock after selling 7,621 shares during the period. American National Bank & Trust’s holdings in Medtronic were worth $7,101,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Monetary Solutions Ltd bought a new stake in shares of Medtronic during the fourth quarter worth $27,000. IAG Wealth Partners LLC bought a new position in Medtronic during the 2nd quarter worth $30,000. Pin Oak Investment Advisors Inc. acquired a new stake in shares of Medtronic in the second quarter valued at about $32,000. Community Bank N.A. acquired a new stake in Medtronic during the 2nd quarter valued at approximately $33,000. Finally, Core Capital Management & Research inc. acquired a new position in shares of Medtronic in the 2nd quarter worth approximately $33,000. Institutional investors and hedge funds own 82.06% of the company’s stock.

Medtronic Trading Down 0.5%

NYSE MDT traded down $0.47 during trading on Wednesday, hitting $86.62. The company had a trading volume of 19,783,249 shares, compared to its average volume of 9,878,357. Medtronic PLC has a one year low of $73.31 and a one year high of $106.33. The company has a market cap of $110.80 billion, a price-to-earnings ratio of 21.35, a price-to-earnings-growth ratio of 2.00 and a beta of 0.55. The company’s fifty day moving average is $90.22 and its 200-day moving average is $84.76. The company has a current ratio of 2.07, a quick ratio of 1.54 and a debt-to-equity ratio of 0.50.

Medtronic (NYSE:MDT) last posted its quarterly earnings data on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.39 by $0.06. The business had revenue of $9.76 billion during the quarter, compared to the consensus estimate of $9.55 billion. Medtronic had a return on equity of 14.78% and a net margin of 13.93%.The firm’s quarterly revenue was up 13.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.26 earnings per share. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. On average, sell-side analysts predict that Medtronic PLC will post 5.98 earnings per share for the current year.

Medtronic Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 16th. Shareholders of record on Friday, September 25th will be paid a dividend of $0.72 per share. The ex-dividend date is Friday, September 25th. This represents a $2.88 dividend on an annualized basis and a yield of 3.3%. Medtronic’s dividend payout ratio (DPR) is presently 70.94%.

Analyst Ratings Changes

MDT has been the topic of a number of research reports. Wall Street Zen upgraded shares of Medtronic from a “hold” rating to a “buy” rating in a research report on Saturday. Royal Bank Of Canada reissued an “outperform” rating and issued a $118.00 price target on shares of Medtronic in a research report on Wednesday, September 2nd. TD Cowen reissued a “buy” rating and set a $110.00 target price on shares of Medtronic in a research report on Wednesday, September 30th. BTIG Research increased their price target on shares of Medtronic from $91.00 to $100.00 and gave the company a “buy” rating in a research report on Tuesday, September 1st. Finally, UBS Group raised their target price on Medtronic from $100.00 to $110.00 and gave the stock a “buy” rating in a research report on Thursday, September 3rd. Eighteen equities research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company. According to MarketBeat.com, Medtronic has an average rating of “Moderate Buy” and an average target price of $102.92.

Insider Buying and Selling at Medtronic

In related news, EVP Harry Kiil sold 1,483 shares of the stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $93.65, for a total transaction of $138,882.95. Following the completion of the sale, the executive vice president owned 42,186 shares in the company, valued at approximately $3,950,718.90. This trade represents a 3.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.27% of the stock is currently owned by insiders.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures devices, therapies and healthcare solutions for treating chronic and acute conditions. Its products are used in areas including cardiac and vascular care, neuroscience, medical and surgical procedures, and diabetes management.

The company’s portfolio includes pacemakers, implantable cardioverter-defibrillators, cardiac ablation systems, stents and other cardiovascular products; neuromodulation systems, deep-brain stimulation devices and spinal technologies; surgical instruments, robotic-assisted surgery systems and gastrointestinal diagnostic tools; and insulin pumps and related diabetes technologies.

Medtronic traces its origins to 1949, when Earl Bakken and Palmer Hermundslie founded the company in Minneapolis, Minnesota.